Breaking Finance News

ADMA Biologics Inc (NDAQ:ADMA) has been upgraded from Mkt Perform to Outperform in a report by Raymond James today.

Raymond James has upgraded ADMA Biologics Inc (NDAQ:ADMA) from Mkt Perform to Outperform in a report released on 11/14/2017.

Just yesterday ADMA Biologics Inc (NDAQ:ADMA) traded 6.64% higher at $2.73. ADMA’s 50-day average is $3.22 and its two hundred day average is $3.60. With the last close down -15.17% relative to the two hundred day average, compared with the S&P 500 Index which has increased 0.02% over the date range. Volume of trade was up over the average, with 64,547 shares of ADMA changing hands over the typical 35,920

See Chart Below

ADMA Biologics Inc (NDAQ:ADMA)

ADMA Biologics Inc has a 52 week low of $2.67 and a 52 week high of $6.88 The company’s market cap is currently $0.

About ADMA Biologics Inc (NDAQ:ADMA)

ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include Plasma Collection Centers, which includes its operations in Georgia; Research and Development, which includes its plasma development operations in New Jersey, and Corporate. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its intravenous immunoglobulin product candidate, RI-002, is intended for the treatment of primary immune deficiency disease.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.